Xerion Healthcare

Xerion Healthcare is the technology commercialization company of University of Oxford.

Xerion Healthcare develop nanoparticles that are used to improve treatment of cancer. The nanoparticles are injected into tumours just prior to standard radiotherapy and act to enhance the effectiveness of the treatment, amplifying the dose of free radicals generated by the X-rays. The nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. Xerion Healthcare are currently developing the treatment for head and neck and pancreatic tumours.